Equities
Results for
"AMGN"
·
·
Last 45 days of the published feed
Clear search
Search intelligence
AMGN market intelligence
Start with the matched tape, then jump to reactions, options flow, proof, or longer articles.
Matched tape
2 shown
Timestamped headlines matching this query.
View matched tape
Reaction only
Price moves
Filter to headlines with market reaction attached.
Show reactions
Options Flow
$620K options
90% calls, 6 trades, 3 sweeps on 2026-09-02
Open flow
Deep dive
AMGN
How Amgen Stock Reacted to Its Q2 2026 Earnings, Measured Minute by Minute
Read article
Equities
Amgen (AMGN) has revealed that its Repatha medication lowers the likelihood of death among patients who are at a high risk of experiencing their first heart attack or stroke. Mkt cap ~$226B
Equity read-through Probabilistic High confidence REGNNVS
REGNNegative
Praluent directly competes with Repatha as an injectable PCSK9 inhibitor for LDL cholesterol reduction.
NVSNegative
Leqvio competes for patients needing additional LDL lowering beyond statins or other lipid therapies.